These results indicate that an IL-25-ILC2-M-MDSC pathway acts independent of IL-33-mediated pathways to produce a cancer-permissive immune niche in APC-mutation-mediated CRC (Figure 3), and may potentially be targeted in patients. This evidence concerns the gene IL25 and cancer.